This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ahead of Conmed (CNMD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Conmed (CNMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Conmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
by Zacks Equity Research
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Is a Beat Likely for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Conmed (CNMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.